Back to results
US 11,685,904 B2Granted
Recombinant vaccinia virus and methods of use thereof
AssigneeIgnite Immunotherapy, Inc.
InventorsDavid H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
Claims15
A replication-competent, recombinant oncolytic vaccinia virus comprising:
- a) a nucleotide sequence encoding a variant herpes simplex virus (HSV) TK polypeptide capable of catalyzing phosphorylation of deoxyguanosine;
- and b) a modification that results in a lack of endogenous thymidine kinase expression or function, wherein the variant HSV TK polypeptide comprises the amino acid sequence of SEQ ID NO:2, 3, or 4.
Dependencies are inferred from the claim text.